Sima Porten, MD, MPH

Genitourinary oncologist

Dr. Sima Porten is a genitourinary cancer specialist and part of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer.

Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter. In studying the biologic basis of urothelial carcinoma using genomic techniques, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer.

Porten received her undergraduate, doctoral and public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Society and also completed a Howard Hughes Medical Institute-National Institutes of Health Research Scholars fellowship. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her urologic oncology fellowship at The University of Texas MD Anderson Cancer Center, she was awarded the John Quale Travel Fellowship for her research in bladder cancer.

Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and the Society of Urologic Oncology.

Clinics

Urologic Surgical Oncology Clinic
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
New Patient Fax: (415) 514-6195
General Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Board Certification

Urology, American Board of Urology

Academic Title

Assistant Professor

More about Sima Porten

Education

Northwestern University Feinberg School of Medicine 2006

Residencies

UCSF Medical Center, Urology 2008

Fellowships

University of Texas MD Anderson Cancer Center, Urologic Oncology 2014

Selected Research and Publications

  1. Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19.
  2. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975.
  3. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582.
  4. Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222.
  5. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2017 Jan 18.
  6. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86.
  7. Porten SP, Leapman MS, Greene KL. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303.
  8. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62.
  9. Sanford T, Porten S, Meng MV. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 2015; 10(8):e0137141.
  10. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90.
  11. Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):517-23.
  12. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51.
  13. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9.
  14. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65.
  15. Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN. Xanthogranulomatous pyelonephritis presenting with a left flank mass. Case Rep Med. 2013; 2013:362194.
  16. Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol. 2014 Feb; 65(2):267-9.
  17. Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013 Sep; 23(5):435-43.
  18. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7.
  19. Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN. Gunshot wounds to the lower urinary tract: a single-institution experience. J Trauma Acute Care Surg. 2013 Mar; 74(3):725-30; discussion 730-1.
  20. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):183-7.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.